Status:
COMPLETED
Glucagon Regulation of Glucose Metabolism
Lead Sponsor:
David D'Alessio, M.D.
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Insulin Secretion
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Glucagon is a 30 amino acid peptide hormone that is produced exclusively in alpha-cells of the pancreatic islets. Glucagon binds to a G-protein coupled receptor and activates intracellular signaling b...
Detailed Description
Subjects will have a screening visit for history, medication usage, and blood work; those who qualify will be offered participation. Subjects will be instructed to consume their usual diet, including ...
Eligibility Criteria
Inclusion
- Healthy, fasting glucose values ≤ 95 mg/dL or A1c ≤ 5.9%, and no first degree family members with T2DM.
Exclusion
- Active infectious, malignant or inflammatory conditions; unstable angina or uncompensated heart failure; pulmonary disorders including COPD and asthma; malabsorptive GI disease; significant hepatic disease; renal insufficiency (eGFR \< 60 ml/kg/min); anemia (hematocrit \< 34%); pregnancy; and uncontrolled hypertension. Subjects will be excluded if they require daily medications that alter glucose metabolism or GI function (glucocorticoids, psychotropics, narcotics, metoclopramide).
Key Trial Info
Start Date :
September 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 16 2021
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT04347252
Start Date
September 24 2019
End Date
April 16 2021
Last Update
May 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Center for Living
Durham, North Carolina, United States, 27705